#Denmark #Copenhagen #TETRAPHARM #Rolf Sass Sørensen #Martin Rose

TETRAPHARM Welcomes Rolf Sass Sørensen as New CEO

On October 6, 2026, TETRAPHARM announced that Rolf Sass Sørensen would take over as Chief Executive Officer. This leadership change comes in the wake of the company's progress in drug development and manufacturing services, previously helmed by co-founder Martin Rose. The transition marks a new chapter for TETRAPHARM, which has aimed to further establish itself in the biopharmaceutical landscape since its inception in 2018.

Rolf Sass Sørensen steps in with an impressive track record, boasting over 30 years of experience within the life sciences sector, particularly in investor relations and corporate communications. Before this appointment, Sørensen served as Vice President of Investor Relations and Communications at Bavarian Nordic. His deep understanding of the biotechnology industry is seen as critical for TETRAPHARM's roadmap moving forward.

Founders Move On but Remain Investors

The co-founders, Martin Rose and Jesper Breum, are transitioning to other biotech ventures but will keep their status as shareholders in TETRAPHARM. Their departure from operational roles does not diminish their contributions, as they have been instrumental in establishing a solid foundation for the company. Both Rose and Breum expressed pride in their achievements and confidence in Sørensen's capabilities to lead the firm to greater success.

Focus on Innovation and Partnerships

Under Sørensen’s leadership, TETRAPHARM will continue its focus on advancing its research and development (R&D) pipeline, which includes promising drug candidates in preclinical stages. A notable aspect of the company's strategy involves utilizing its proprietary drug delivery technology, ZYNDIKATE®, which has applications in pharmaceutical formulation and manufacturing. The CEO emphasized the importance of marrying scientific advancements with clear business priorities and execution strategies.

"The unique combination of science, technology, and partnerships at TETRAPHARM offers a compelling platform for growth," Sørensen stated. "My role will be to ensure that this potential translates into measurable outcomes and sustained progress for our organization."

The Future Looks Bright for TETRAPHARM

As the company strives to innovate and impact the healthcare industry positively, it looks to capitalize on its successful foundations laid by the previous leadership. With new direction and a continued commitment to excellence, the future of TETRAPHARM is promising.

For media inquiries or more detailed information, please reach out to Jacob Schlundt, Chief Marketing Officer of TETRAPHARM, at [email protected] and +45 5197 6225.

TETRAPHARM's headquarters remain in Copenhagen. As a biopharmaceutical firm, the company emphasizes the development of drug candidates aimed at addressing issues within the central nervous system and immune system, alongside providing contract development and manufacturing services for pharmaceuticals.

With Rolf Sass Sørensen at the helm, TETRAPHARM is poised for a transformative journey that promises to enhance its offerings and establish it further in the biopharmaceutical space.